MRI靶向前列腺活检如何改变前列腺癌放疗方案
该研究分析533例同时接受MRI/超声融合靶向活检(TB)和系统活检(SB)的男性,比较两种活检方法对癌症风险分类及放疗推荐的影响。结果发现TB常导致风险分类升级,从而推荐更激进的放疗方案。
要点
- TB较SB更常将患者重新分类至更高风险组。
- 风险分类变化导致更激进的放疗推荐。
- 在主动监测和既往阴性活检队列中差异显著。
核心结论
- 在男性前列腺癌患者中,与单独SB结果相比,TB常导致更高风险组重新分类,并伴随更激进的放疗推荐。
研究设计与样本
- 回顾性分析533例2014至2017年同时接受TB和SB的男性临床病理数据。
- 队列包括活检初治80/533(15.0%)、主动监测185/533(34.7%)和既往阴性活检268/533(50.3%)。
主要发现
- 所有患者中,TB使风险分类从「无癌或低风险」升至「不利 intermediate 风险」(30/343,P<0.0001)和「高风险」(31/353,P<0.0001)。
临床怎么用
- 临床解读前列腺癌风险分类和放疗推荐时需考虑活检方法(TB vs SB)的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine if magnetic resonance imaging (MRI)/ultrasound fusion-targeted prostate biopsy (TB) would lead to increased recommendations of aggressive radiotherapy treatments for higher risk prostate cancer compared to systematic biopsy (SB) results. METHODS: Clinicopathologic data of 533 men who underwent both TB and SB from 2014 to 2017 was analyzed. TB was performed in addition to SB in patients with detection of MRI suspicious lesions. Three patient cohorts were established: (1) biopsy naïve (80/533, 15.0%), (2) active surveillance (185/533, 34.7%), and (3) prior negative biopsy (268/533, 50.3%). Cancer risk categorical criteria were established with recommended radiotherapy treatment for each. Variation of risk classification due to biopsy method for all patients and within each cohort was analyzed using either a chi-squared statistic or Fisher's exact test. McNemar's pairwise analyses were performed for all risk categories between TB and SB to assess the effects of TB on high-risk cancer identification and subsequent radiotherapy recommendations. RESULTS: Number of patients within cancer risk categories (1. "No Cancer or Low-Risk"; 2. "More Favorable Intermediate-Risk"; 3. "Less Favorable Intermediate-Risk"; 4. "High-Risk") varied significantly based on TB and SB pathology among all patients combined (P <.0001), in cohort 2 (P = .0005), and in cohort 3 (P <0.0001). Further, among all patients, TB increased cancer risk classification and correspondingly would result in more aggressive radiotherapy recommendations: "No Cancer or Low-Risk" to "Less Favorable Intermediate-Risk" (30/343, P <0.0001) and "No Cancer or Low-Risk" to "High-Risk" (31/353, P <.0001). CONCLUSION: Among men with prostate cancer, TB commonly led to reclassification to a higher risk group, which is accompanied by more aggressive radiotherapy treatment recommendations when compared with SB findings alone.
引用
- Dix DB, McDonald AM, Gordetsky JB, et al. How Would MRI-targeted Prostate Biopsy Alter Radiation Therapy Approaches in Treating Prostate Cancer? Urology. 2018. PMID: 30172834. doi:10.1016/j.urology.2018.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。